Biomarin Pharmaceutical (BMRN) Gross Profit (2009 - 2026)

Biomarin Pharmaceutical has disclosed Gross Profit across 18 years of filings, most recently posting $571.2 million for Q1 2026.

• Quarterly Gross Profit fell 3.77% year-over-year to $571.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 billion (up 5.88% YoY) and the FY2025 annual result came in at $2.5 billion, up 10.12% from the prior year.
• Gross Profit eased to $571.2 million in Q1 2026, from $598.9 million in the prior quarter.
• Over five years, Gross Profit peaked at $675.3 million in Q2 2025 and troughed at $389.1 million in Q3 2022.
• A 5-year average of $519.3 million and a median of $523.7 million in 2024 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2023 — Gross Profit soared 30.03% — and 2026, when it declined 3.77%.
• Tracing BMRN's Gross Profit over 5 years: stood at $390.9 million in 2022, then surged by 30.03% to $508.3 million in 2023, then rose by 20.24% to $611.2 million in 2024, then dropped by 2.02% to $598.9 million in 2025, then dropped by 4.62% to $571.2 million in 2026.
• Business Quant data shows BMRN's Gross Profit at $571.2 million in Q1 2026, $598.9 million in Q4 2025, and $636.0 million in Q3 2025.